Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
Top Cited Papers
Open Access
- 16 August 2011
- journal article
- research article
- Published by Springer Nature in International Journal of Obesity
- Vol. 36 (6) , 843-854
- https://doi.org/10.1038/ijo.2011.158
Abstract
Objective: Design: Subjects: Results: Conclusion:Keywords
This publication has 33 references indexed in Scilit:
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese SubjectsNew England Journal of Medicine, 2010
- Changes in Inflammatory Biomarkers Across Weight Classes in a Representative US Population: A Link Between Obesity and InflammationJournal of Gastrointestinal Surgery, 2009
- Beneficial effects of once‐daily liraglutide, a human glucagon‐like peptide‐1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetesDiabetic Medicine, 2008
- Can we predict future improvement in glycaemic control? Response to Singh and Press, 2008Diabetic Medicine, 2008
- Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 DiabetesDiabetes Care, 2007
- Definition of Metabolic SyndromeCirculation, 2004
- Long-term pharmacotherapy for obesity and overweightCochrane Database of Systematic Reviews, 2003
- World Medical Association Declaration of HelsinkiJAMA, 2000
- Executive SummaryObesity Research, 1998
- A Multiple Comparison Procedure for Comparing Several Treatments with a ControlJournal of the American Statistical Association, 1955